Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Neptune Subsidiary to Develop OTC, MF & Rx Products - Nutraceuticals World
Market Updates

Neptune Subsidiary to Develop OTC, MF & Rx Products

Neptune Technologies Bioressources, Laval, Quebec, Canada, has formed an operating pharmaceutical subsidiary named Acasti Pharma Inc., which will carry out the research, development and commercialization of active pharmaceutical ingredients for cardiovascular disease. According to its business strategy, Acasti Pharma will pursue negotiations with the objective of entering strategic pharmaceutical alliances. Neptune has granted Acasti Pharma a license to rights of its intellectual property (IP) portfolio related to cardiovascular applications, allowing the group to develop novel active pharmaceutical ingredients into commercial products for three pharmaceutical markets, namely the over-the-counter (OTC), the medical food (MF) and the prescription drug (Rx) markets. Acasti Pharma is preparing an investigational new drug application for FDA and a clinical trial application with Health Canada. Acasti Pharma is working to advance a portfolio of proprietary novel omega 3 phospholipids through the pharmaceutical development pathway for prescription MF, OTC and Rx applications.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters